ArticlePloS one2015
Where Failure Is Not an Option -Personalized Medicine in Astronauts.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 41 citations in OpenAlex.
- Feasibility of dried blood spot collection for caffeine pharmacokinetic studies in microgravity: Insights from parabolic flight campaigns.British journal of clinical pharmacology · 2026Article
- Evolutionary medicine and bioastronautics: an innovative approach in addressing adverse mental health effects to astronauts during long term space missions.Frontiers in physiology · 2025Article
- Pharmacological Innovations in Space: Challenges and Future Perspectives.Pharmaceutical research · 2024Review
- Expiration analysis of the International Space Station formulary for exploration mission planning.NPJ microgravity · 2024Article
- Astronaut omics and the impact of space on the human body at scale.Nature communications · 2024Review
- Enhancing European capabilities for application of multi-omics studies in biology and biomedicine space research.iScience · 2023Review
- To infinity and beyond: Strategies for fabricating medicines in outer space.International journal of pharmaceutics: X · 2022Article
- Routine omics collection is a golden opportunity for European human research in space and analog environments.Patterns (New York, N.Y.) · 2022Review
- Physiological adaptations affecting drug pharmacokinetics in space: what do we really know? A critical review of the literature.British journal of pharmacology · 2022Review
- The Future of Personalized Medicine in Space: From Observations to Countermeasures.Frontiers in bioengineering and biotechnology · 2021Review
- A New Era for Space Life Science: International Standards for Space Omics Processing.Patterns (New York, N.Y.) · 2020Review
- Personalised Medicine: implication and perspectives in the field of occupational health.La Medicina del lavoro · 2020Article
- Medications in Space: In Search of a Pharmacologist's Guide to the Galaxy.Pharmaceutical research · 2019Review
- Drug Interactions in Space: a Cause for Concern?Pharmaceutical research · 2019Article
- The gravity dependence of pharmacodynamics: the integration of lidocaine into membranes in microgravity.NPJ microgravity · 2019Article
- [Personalized drug therapy based on genetics. Possibilities and examples from clinical practice].Der Internist · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug safety and efficacy are highly variable among patients. Most patients will experience the desired drug effect, but some may suffer from adverse drug reactions or gain no benefit. Pharmacogenetic testing serves as a pre-treatment diagnostic option in situations where failure or adverse events should be avoided at all costs. One such situation is human space flight. On the international space station (ISS), a list of drugs is available to cover typical emergency settings, as well as the long-term treatment of common conditions for the use in self-medicating common ailments developing over a definite period. Here, we scrutinized the list of the 78 drugs permanently available at the ISS (year 2014) to determine the extent to which their metabolism may be affected by genetic polymorphisms, potentially requiring genotype-specific dosing or choice of an alternative drug. The purpose of this analysis was to estimate the potential benefit of pharmacogenetic diagnostics in astronauts to prevent therapy failure or side effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.